Stifel raised the firm’s price target on Crinetics (CRNX) to $75 from $58 and keeps a Buy rating on the shares after updating the firm’s model following last week’s approval of Palsonify in acromegaly. The price point of $290,000 per year came in well-above expectations of parity to a marginal premium to standard-of-care SRLs and improves the set-up, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics price target raised to $77 from $65 at Morgan Stanley
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- Crinetics rises 25.7%
- Crinetics rises 21.9%
- Crinetics price target raised to $62 from $58 at Baird